Stuart Isaacson
YOU?
Author Swipe
View article: 3483 Evaluation of infusion site adverse events with foslevodopa/foscarbidopa in a 12 week, randomized study
3483 Evaluation of infusion site adverse events with foslevodopa/foscarbidopa in a 12 week, randomized study Open
View article: Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease Open
Background As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24‐hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor …
View article: Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab Open
Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody p…
View article: Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial
Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial Open
NCT02610868.
View article: Safety and Efficacy of Istradefylline in Parkinson’s Disease Patients With and Without Preexisting Dyskinesia: Pooled Analysis of 8 Randomized Controlled Trials
Safety and Efficacy of Istradefylline in Parkinson’s Disease Patients With and Without Preexisting Dyskinesia: Pooled Analysis of 8 Randomized Controlled Trials Open
Objective To evaluate the efficacy of istradefylline in Parkinson’s disease patients experiencing motor fluctuations with and without dyskinesia and characterize potential predictors for treatment-emergent dyskinesia with istradefylline.Me…
View article: Management of Parkinson’s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching
Management of Parkinson’s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching Open
PDP is a common but still undertreated sequela of PD progression. Pimavanserin is recommended as a first-line antipsychotic therapy based on its established safety and efficacy. While switching strategies are suggested, further study is ne…
View article: Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study
Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study Open
Background Continuous subcutaneous apomorphine infusion (CSAI) has been used globally since the 1980s for Parkinson disease (PD) motor fluctuations but has not been available in the United States (US). Objective Evaluate CSAI for motor flu…
View article: A Pilot Study of AI-Controlled Transcutaneous Peripheral Nerve Stimulation for Essential Tremor
A Pilot Study of AI-Controlled Transcutaneous Peripheral Nerve Stimulation for Essential Tremor Open
In an uncontrolled pilot study, an AI-controlled transcutaneous peripheral nerve stimulation device was worn continuously during waking hours for 7 to 10 days by patients with essential tremor. Tremor statistically significantly decreased …
View article: Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease
Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease Open
View article: Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease
Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease Open
View article: Long-Term Dementia Risk in Parkinson Disease
Long-Term Dementia Risk in Parkinson Disease Open
Results from two large, prospective studies suggest that dementia in PD occurs less frequently, or later in the disease course, than previous research studies have reported.
View article: Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study Open
Estimates of the spectrum and frequency of pathogenic variants in Parkinson’s disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the…
View article: Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study Open
View article: Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies
Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies Open
Importance Finding a reliable diagnostic biomarker for the disorders collectively known as synucleinopathies (Parkinson disease [PD], dementia with Lewy bodies [DLB], multiple system atrophy [MSA], and pure autonomic failure [PAF]) is an u…
View article: Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia Open
This study provides Class I evidence that in adults with moderate-to-severe idiopathic cervical dystonia, DAXI reduces dystonia more effectively than placebo.
View article: Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis
Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis Open
Pimavanserin did not increase the MR in PDP. Pimavanserin's MR appears to be comparable to or lower than other atypical antipsychotics prescribed for PDP, including quetiapine.
View article: Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9 (2023) 100223]
Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9 (2023) 100223] Open
[This corrects the article DOI: 10.1016/j.prdoa.2023.100223.].
View article: Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel
Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel Open
Experts generally reached consensus that apomorphine can usually be prescribed without antiemetic pretreatment. Recommendations described here reflect the areas of greatest agreement among a panel of experts based on current available evid…
View article: IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease Open
Importance Levodopa has a short half-life and a limited window of opportunity for absorption in the proximal small intestine. IPX203 is an oral, extended-release formulation of carbidopa-levodopa developed to address these limitations. Obj…
View article: Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel Open
View article: Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT <sub>1A</sub> Agonist, in Patients With Parkinson Disease Psychosis
Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT <sub>1A</sub> Agonist, in Patients With Parkinson Disease Psychosis Open
This Class II study was an exploratory pilot study that was underpowered to detect a statistically significant difference between ulotaront and placebo in the treatment of patients with Parkinson disease psychosis without worsening motor f…
View article: Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?
Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary? Open
Background: Nausea is common upon initiating dopamine agonists in patients with Parkinson’s disease (PD); however, pretreatment with an antiemetic is recommended only when initiating apomorphine formulations. Objective: Evaluate the need f…
View article: Expert Consensus on the Use of <scp><i>On</i>‐Demand</scp> Treatments for <scp>OFF</scp> Episodes in Parkinson's Disease: A Modified Delphi Panel
Expert Consensus on the Use of <span><i>On</i>‐Demand</span> Treatments for <span>OFF</span> Episodes in Parkinson's Disease: A Modified Delphi Panel Open
Background On‐demand treatments can treat OFF episodes in Parkinson's disease, however, there is limited information regarding when to prescribe them. Objective Develop expert consensus to determine appropriate clinical factors for conside…
View article: Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson’s Disease
Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson’s Disease Open
Objective, clinician-rated, and patient-rated assessments demonstrated that TAPS provided clinically meaningful relief of action tremor in patients with PD.
View article: Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment Open
View article: Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study
Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study Open
Background: Dose optimization of sublingual apomorphine (SL-APO), a dopamine agonist for the treatment of OFF episodes in patients with Parkinson’s disease (PD), has been performed under clinical supervision in clinical trials. SL-APO may …
View article: Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease
Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease Open
View article: Motor Response With Apomorphine Sublingual Film and Levodopa in Patients With OFF Episodes
Motor Response With Apomorphine Sublingual Film and Levodopa in Patients With OFF Episodes Open
Aim: Evaluate timing of motor improvement with carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO) in patients with Parkinson's disease and OFF episodes. Methods: A post hoc pooled analysis from two stu…
View article: How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature
How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature Open
Based on the reviewed trials and our clinical experience, we suggest that subcutaneous apomorphine therapy can be initiated using a slow titration scheme without antiemetic pretreatment.
View article: Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial Open